A method for predicting the response of a patient diagnosed with non-small-cell lung carcinoma, to a medicament, wherein the response of said patient to said medicament is the time to progression upon treatment with said medicament, comprising the steps of: (a) measuring the kinase activity of a blood sample, obtained from said patient diagnosed with non-small-cell lung carcinoma, by contacting said sample with at least one protein kinase substrate, thereby providing a phosphorylation profile of said sample, said phosphorylation profile comprising the phosphorylation levels of phosphorylation sites present in at least peptide markers with SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 14 and 21; and (b) determining from said phosphorylation profile the response of said patient to said medicament; wherein the response of said patient to said medicament is determined from said phosphorylation profile by (i) calculating a classifier parameter from said phosphorylation profile; and (ii) determining the response of said patient to said medicament on the basis of said classifier parameter; or wherein the response of said patient to said medicament is determined from said phosphorylation profile by (iii) comparing said phosphorylation profile to a first and a second reference phosphorylation profile; said first reference phosphorylation profile being representative for a good responder to said medicament and said second reference phosphorylation profile being representative for a poor responder to said medicament; wherein the good responder has a late or no progression of disease upon treatment with said medicament and the poor responder has an early progression of disease upon treatment with said medicament; and (iv) determining response of said patient to said medicament on the basis of the comparison of said phosphorylation profile with said first and said second reference phosphorylation profile. (a) measuring the kinase activity of a blood sample, obtained from said patient diagnosed with non-small-cell lung carcinoma, by contacting said sample with at least one protein kinase substrate, thereby providing a phosphorylation profile of said sample, said phosphorylation profile comprising the phosphorylation levels of phosphorylation sites present in at least peptide markers with SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 14 and 21; and (b) determining from said phosphorylation profile the response of said patient to said medicament; wherein the response of said patient to said medicament is determined from said phosphorylation profile by (i) calculating a classifier parameter from said phosphorylation profile; and (ii) determining the response of said patient to said medicament on the basis of said classifier parameter; or (i) calculating a classifier parameter from said phosphorylation profile; and (ii) determining the response of said patient to said medicament on the basis of said classifier parameter; or wherein the response of said patient to said medicament is determined from said phosphorylation profile by (iii) comparing said phosphorylation profile to a first and a second reference phosphorylation profile; said first reference phosphorylation profile being representative for a good responder to said medicament and said second reference phosphorylation profile being representative for a poor responder to said medicament; wherein the good responder has a late or no progression of disease upon treatment with said medicament and the poor responder has an early progression of disease upon treatment with said medicament; and (iv) determining response of said patient to said medicament on the basis of the comparison of said phosphorylation profile with said first and said second reference phosphorylation profile. <EOS>